Leukemia 2000, 14 (2) : 262–270.CrossRefPubMed 18. Karlsson J, Ora I, Porn-Ares Bcl-2 inhibitor I, Pahlman S: Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004, 10 (9) : 3179–3188.CrossRefPubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions As principle investigator HL and HC had full access to all of the data in this study and take responsibility for the accuracy of the data analysis. Study concept and design:
HL, XZ and JX. MTT, Clonogenic assay, Flow cytometry assay, TUNEL assay and western blot: XZ, HL. Analysis and interpretation of data: XZ, HL. Drafting of the manuscript: HL, XZ. Critical revision of the manuscript: JX, HC. Supervision: YZ, JX and HC.”
“Background A high response rate has been reported for LCL161 solubility dmso FOLFOX therapy that includes oxaliplatin in patients with unresectable
advanced/recurrent colorectal cancer, and this therapy is now established as one of the standard treatment option [1, 2]. Since the introduction of oxaliplatin to Japan in April 2005, FOLFOX therapy has also become widely used in this country and is recommended as one of the standard treatments [3]. There check details are a number of versions of FOLFOX therapy among which modified FOLFOX6 (mFOLFOX6) allows more convenient administration and has been adopted by many medical institutions in association with popularization of outpatient chemotherapy. However, there have been few adequate investigations into the safety and efficacy of mFOLFOX6 therapy.
A rapid increase in the incidence of colorectal cancer among elderly Japanese persons is anticipated in the future, considering the current long average life span and the increase in the incidence and mortality of colorectal cancer in Japan. However, it remains controversial Sulfite dehydrogenase as to whether the same multi-drug chemotherapy employed for younger patients should also be given to elderly patients, because an increase in the severity of adverse events is likely in the elderly due to the decline of organ function associated with ageing. Accordingly, the present study was performed to examine the safety and efficacy of mFOLFOX6 therapy in patients over 70 years old. Subjects and methods Subjects A multicenter study on the treatment of unresectable advanced/recurrent colorectal cancer was started in 2006 by the Sanin Study Group on colorectal cancer (SSCC). To determine whether mFOLOFX6 could be used safely to treat unresectable advanced/recurrent colorectal cancer in elderly patients, the present study (SSCC-0601) was also performed by the SSCC.